Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Dermatology
Published in: BMC Dermatology 1/2019

Open Access 01-12-2019 | Atopic Dermatitis | Research article

Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis

Authors: Eric Simpson, Laurent Eckert, Abhijit Gadkari, Usha G. Mallya, Min Yang, Lauren Nelson, Michelle Brown, Matt Reaney, Puneet Mahajan, Isabelle Guillemin, Mark Boguniewicz, David Pariser

Published in: BMC Dermatology | Issue 1/2019

Login to get access

Abstract

Background

The Atopic Dermatitis Control Tool (ADCT©) is a brief patient self-administered instrument designed and validated to assess atopic dermatitis (AD) control; six AD symptoms and impacts are evaluated over the past week, including overall severity of symptoms, days with intense episodes of itching, intensity of bother, problem with sleep, impact on daily activities, and impact on mood or emotions. This study assessed the reliability, validity, and responsiveness of the ADCT in a longitudinal context, and provided thresholds to identify meaningful within-person change.

Methods

Data were from a prospective, longitudinal patient survey study of real-world effectiveness of dupilumab in patients with AD. Eligible patients completed a baseline survey before starting dupilumab and were followed at Months 1, 2, 3, and 6 post-initiation as they became eligible.

Results

Psychometric analyses confirmed internal consistency; Cronbach’s α coefficients were consistently above the threshold of 0.70 across each follow-up; item-to-total correlations were above the threshold of r ≥ 0.50. High correlations between the ADCT and the Dermatology Life Quality Index (DLQI) and skin pain supported construct validity, while known-group validity was shown on Patient Global Assessment of Disease (PGAD) overall well-being subgroups with worse AD-related overall well-being having higher mean ADCT total scores at all time points. The ability of the ADCT to detect change was confirmed; the threshold for meaningful within-person change was estimated to be 5 points. Finally, test–retest reliability was confirmed in subgroups of patients with stable PGAD responses.

Conclusions

Our findings confirm that the ADCT is a valid and reliable tool for assessing AD control.
Literature
1.
Brunner PM, Silverberg JI, Guttman-Yassky E, Paller AS, Kabashima K, Amagai M, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137(1):18–25.PubMedCrossRef
2.
Thijs JL, Strickland I, Bruijnzeel-Koomen C, Nierkens S, Giovannone B, Knol EF, et al. Serum biomarker profiles suggest that atopic dermatitis is a systemic disease. J Allergy Clin Immunol. 2018;141(4):1523–6.PubMedCrossRef
3.
4.
5.
Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis--part I: clinical and pathologic concepts. J Allergy Clin Immunol. 2011;127(5):1110–8.PubMedCrossRef
6.
Simpson EL, Guttman-Yassky E, Margolis DJ, Feldman SR, Qureshi A, Hata T, et al. Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis. JAMA Dermatol. 2018;154(8):903–12.PubMedPubMedCentralCrossRef
7.
Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73:1284–93.PubMedCrossRef
8.
Girolomoni G, Gadkari A, Auziere S, Puig L, Barbarot S, Chosidow O, et al. The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Canada and Europe. Value Health. 2017;20(9):A807.CrossRef
9.
Dalgard FJ, Gieler U, Tomas-Aragones L, Lien L, Poot F, Jemec GBE, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984–91.PubMedPubMedCentralCrossRef
10.
Simpson EL, Bieber T, Eckert L, Wu R, Ardeleanu M, Graham NM, et al. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016;74(3):491–8.PubMedCrossRef
11.
Yano C, Saeki H, Ishiji T, Ishiuji Y, Sato J, Tofuku Y, et al. Impact of disease severity on work productivity and activity impairment in Japanese patients with atopic dermatitis. J Dermatol. 2013;40(9):736–9.PubMedCrossRef
12.
Whiteley J, Emir B, Seitzman R, Makinson G. The burden of atopic dermatitis in US adults: results from the 2013 National Health and wellness survey. Curr Med Res Opin. 2016;32:1645–51.PubMedCrossRef
13.
Sandhu JK, Wu KK, Bui TL, Armstrong AW. Association between atopic dermatitis and suicidality: a systematic review and meta-analysis. JAMA Dermatol. 2019;155(2):178–87.PubMedCrossRef
14.
Bender BG, Ballard R, Canono B, Murphy JR, Leung DY. Disease severity, scratching, and sleep quality in patients with atopic dermatitis. J Am Acad Dermatol. 2008;58(3):415–20.PubMedCrossRef
15.
Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338–51.PubMedCrossRef
16.
Chalmers JR, Thomas KS, Apfelbacher C, Williams HC, Prinsen CA, Spuls PI, et al. Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). Br J Dermatol. 2018;178(5):e332–41.PubMedCrossRef
17.
Schmitt J, Spuls P, Boers M, Thomas K, Chalmers J, Roekevisch E, et al. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. Allergy. 2012;67(9):1111–7.PubMedCrossRef
18.
Leung DY, Guttman-Yassky E. Assessing the current treatment of atopic dermatitis: unmet needs. J Allergy Clin Immunol. 2017;139(4S):S47–8.PubMedCrossRef
19.
European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European task force on atopic dermatitis. Dermatology. 1993;186(1):23–31.CrossRef
20.
Wei W, Anderson P, Gadkari A, Blackburn S, Moon R, Piercy J, et al. Discordance between physician- and patient-reported disease severity in adults with atopic dermatitis: a US cross-sectional survey. Am J Clin Dermatol. 2017;18(6):825–35.PubMedPubMedCentralCrossRef
21.
Schmitt J, Spuls PI, Thomas KS, Simpson E, Furue M, Deckert S, et al. The Harmonising outcome measures for eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol. 2014;134(4):800–7.PubMedCrossRef
22.
Yosipovitch G, Eckert L, Chen Z, Ardeleanu M, Shumel B, Plaum S, et al. P480 correlations of itch with quality of life and signs of atopic dermatitis across dupilumab trials. Ann Allergy Asthma Immunol. 2017;119(5):S95.CrossRef
23.
Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol. 2004;140(12):1513–9.PubMedCrossRef
24.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)- a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–6.PubMedCrossRef
25.
Zuberbier T, Orlow SJ, Paller AS, Taieb A, Allen R, Hernanz-Hermosa JM, et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):226–32.PubMedCrossRef
26.
Reitamo S, Allsopp R. Treatment with twice-weekly tacrolimus ointment in patients with moderate to severe atopic dermatitis: results from two randomized, multicentre, comparative studies. J Dermatolog Treat. 2010;21(1):34–44.PubMedCrossRef
27.
Ortiz de Frutos FJ, Torrelo A, de Lucas R, Gonzalez MA, Alomar A, Vera A, et al. Patient perspectives on triggers, adherence to medical recommendations, and disease control in atopic dermatitis: the DATOP study. Actas Dermosifiliogr. 2014;105:487–96.PubMedCrossRef
28.
Meurer M, Lubbe J, Kapp A, Schneider D. The role of pimecrolimus cream 1% (Elidel) in managing adult atopic eczema. Dermatology. 2007;215(Suppl 1):18–26.PubMedCrossRef
29.
Abuabara K, Hoffstad O, Troxel A, Gelfand JM, Margolis DJ. Atopic dermatitis disease control and age: a cohort study. J Allergy Clin Immunol. 2015;136(1):190–2 e193.PubMedPubMedCentralCrossRef
30.
31.
32.
Cortina J. What is coefficient alpha? An examination of theory and applications. J Appl Psychol. 1993;78(1):98.CrossRef
33.
Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86(2):420–8.PubMedCrossRef
34.
Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007;60(1):34–42.PubMedCrossRef
35.
36.
Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol. 2005;125(4):659–64.PubMedCrossRef
37.
Durlak JA. How to select, calculate, and interpret effect sizes. J Pediatr Psychol. 2009;34(9):917–28.PubMedCrossRef
38.
Streiner DL, Norman GR, Cairney J. Health measurement scales: a practical guide to their development and use. 5th ed. New York: Oxford University Press; 2015.CrossRef
39.
Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the dermatology life quality index (DLQI): further data. Dermatology. 2015;230(1):27–33.PubMedCrossRef
40.
Metadata
Title
Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis
Authors
Eric Simpson
Laurent Eckert
Abhijit Gadkari
Usha G. Mallya
Min Yang
Lauren Nelson
Michelle Brown
Matt Reaney
Puneet Mahajan
Isabelle Guillemin
Mark Boguniewicz
David Pariser
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Dermatology / Issue 1/2019
Electronic ISSN: 1471-5945
DOI
https://doi.org/10.1186/s12895-019-0095-3

Other articles of this Issue 1/2019

BMC Dermatology 1/2019 Go to the issue

Research article

Pattern of skin diseases in children attending a dermatology clinic in a referral hospital in Wolaita Sodo, southern Ethiopia

Study protocol

Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America

Research article

Differences in microRNA expression between melanoma and healthy adjacent skin

Case report

Gluteal hidradenitis suppurativa presenting pemphigus-like findings: case report

Research article

Diaper dermatitis: a survey of risk factors in Thai children aged under 24 months

Case report

Ainhum, a rare mutilating dermatological disease in a female Cameroonian: a case report